NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today physician experience from a large cohort of 25 epilepsy patients treated with the OneRF Ablation System at Mayo Clinic in Jacksonville, Florida. The team, led by neurologist Dr. Brin Freund and the late neurosurgeon Dr. Sanjeet Grewal, performed radiofrequency (RF) ablations on patients with drug-resistant focal epilepsy after diagnostic stereo-EEG (SEEG) monitoring with NeuroOne electrodes.
The physicians reported that the procedure was well tolerated, with rare short-term effects and no serious long-term complications. The majority of patients experienced meaningful reductions in seizure frequency, while some achieved sustained seizure freedom either directly after RF ablation or after subsequent surgical or medical therapy guided by data from the ablation. Most patients also reported improved quality of life and satisfaction with the procedure. Ablation targets ranged from small, discrete seizure areas to multifocal or more extensively distributed epileptic networks.
Dr. Freund commented, “NeuroOne SEEG-guided radiofrequency thermocoagulation is a minimally invasive procedure that can be performed at the bedside through the same implanted diagnostic electrodes used to localize a patient's seizures. ... This approach has changed how we treat drug-resistant focal epilepsy and is now part of the standard of care at Mayo Clinic Florida.” Dave Rosa, CEO of NeuroOne, said, “These results validate our long-held belief that, for patients already undergoing diagnostic SEEG, the ability to potentially deliver meaningful therapeutic benefit through the same implanted electrodes represents a compelling clinical and economic value proposition. ... As the only FDA-cleared platform combining SEEG diagnosis and RF ablation using the same sEEG device, we believe NeuroOne is uniquely positioned to support this evolving diagnosis-to-therapy treatment paradigm.”
This real-world evidence is significant because it demonstrates a potential paradigm shift in epilepsy treatment: instead of separate diagnostic and therapeutic procedures, patients can undergo diagnosis and therapy in a single monitoring period. The OneRF system's proprietary temperature monitoring technology provides real-time feedback, allowing physicians to assess ablation effectiveness immediately and perform additional targeted ablations if needed. This approach could reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes. For more information, visit nmtc1.com.
